Holen Sie sich die Stockscreener-App
6.85
1.86%
-0.13
Handel nachbörslich:
6.85
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt SLDB?
Forum
Prognose
Aktiensplit
Solid Biosciences Inc Aktie (SLDB) Neueste Nachrichten
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Solid Biosciences is a speculative buy with pro... - Pluang
Solid Biosciences: A Funded Challenge To Duchenne Gene Therapy’s Limitations (NASDAQ:SLDB) - Seeking Alpha
New data from Solid Biosciences to be shared at neuromuscular research event - Traders Union
Solid Biosciences stock edges lower as investors weigh recent gains and fundamentals - AD HOC NEWS
Solid Biosciences stock gains on fresh analyst upgrades and DMD outlook - AD HOC NEWS
Solid Biosciences Inc.Common Stock (Nasdaq:SLDB) Detailed Stock Data - The Chronicle-Journal
Solid Biosciences stock gains on analyst upgrade and growing gene therapy pipeline - AD HOC NEWS
Solid Biosciences wins new Outperform at RBC on DMD opportunity - Seeking Alpha
Solid Biosciences' Duchenne Muscular Dystrophy Approach, FDA Shift Support Upside, RBC Says - Yahoo Finance
Leerink Partners Initiates Solid Biosciences(SLDB.US) With Buy Rating, Announces Target Price $20 - Moomoo
SLDB Initiated Coverage by RBC Capital -- Rating Set at Outperfo - GuruFocus
RBC Initiates Solid Biosciences at Outperform, Speculative Risk With $18 Price Target - marketscreener.com
Solid Biosciences LLC (NASDAQ: SLDB) Share Price, SLDB Stock News, SLDB Share Price & Updates - kalkine.com.au
SLDB: Advancing novel gene therapies for DMD and FA, with pivotal FDA meetings and data ahead - TradingView
SLDB Reiterated by HC Wainwright & Co. -- Price Target Maintained at $25 - GuruFocus
H.C. Wainwright reiterates Solid Biosciences stock rating at buy By Investing.com - Investing.com Canada
Solid Biosciences at Citi summit: FDA tests loom for gene therapy push - Investing.com Canada
Solid Biosciences Q2 2026 Earnings: Narrower Loss Beats Estimates, but Shares SlipProfit Growth Outlook - dars.gov.et
Solid Biosciences at Cantor Fitzgerald conference: 2025 catalyst push By Investing.com - Investing.com India
SLDB: Pivotal gene therapy data and regulatory milestones for DMD and FA expected in early 2025 - TradingView
Solid Biosciences Stock Price Forecast. Should You Buy SLDB? - StockInvest.us
Solid Biosciences Insiders Sell US$823k Of Stock, Possibly Signalling Caution - simplywall.st
Solid Biosciences to Participate at Upcoming Investor Conferences - GlobeNewswire
Analysts Offer Insights on Healthcare Companies: NeoGenomics (NEO), LeonaBio (LONA) and Solid Biosciences (SLDB) - The Globe and Mail
Cantor raises Solid Biosciences stock price target on gene therapy - Investing.com
Cantor raises Solid Biosciences stock price target on gene therapy By Investing.com - Investing.com Canada
Cantor Fitzgerald Maintains Solid Biosciences(SLDB.US) With Buy Rating, Raises Target Price to $26 - Moomoo
Daniel Fischer and Ilan Ganot: The Parent-CEOs Who Turned Their Children's Diagnoses into Biotech Missions - finance.biggo.com
Solid Biosciences Inc (SLDB) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
SLDB Maintained by Truist Securities -- Price Target Raised to $20 - GuruFocus
Solid Biosciences (NASDAQ:SLDB) Earns Buy Rating from Analysts at Truist Financial - MarketBeat
Truist Financial Initiates Solid Biosciences(SLDB.US) With Buy Rating, Announces Target Price $20 - Moomoo
Solid Biosciences (NASDAQ:SLDB) Stock Price Down 6.7%Time to Sell? - MarketBeat
Solid Biosciences Inc. (NASDAQ:SLDB) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Solid Biosciences Inc. brings patient advocates to FA panel at GMP Lab - Traders Union
Perceptive Advisors (NASDAQ: SLDB) details 11.2% beneficial stake and warrant limits - Stock Titan
Solid Biosciences (SLDB): Vestal Point Capital discloses 4.8% ownership, including warrant shares - Stock Titan
Solid Biosciences (SLDB) Holds Steady Near $9.09 as Gene Therapy Sector Watches Key LevelsVolume Weighted Price - vinanet.vn
HC Wainwright Has Positive Estimate for SLDB Q3 Earnings - MarketBeat
Form 8K Solid Biosciences LLC For: 6 August By Investing.com - Investing.com Nigeria
J.P. Morgan Maintains Solid Biosciences(SLDB.US) With Buy Rating, Maintains Target Price $11 - Moomoo
Dimensional Fund Advisors LP Acquires 277,051 Shares of Solid Biosciences Inc. $SLDB - MarketBeat
Solid Biosciences Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Citizens reiterates Solid Biosciences stock rating on pipeline progress By Investing.com - Investing.com Nigeria
Citizens reiterates Solid Biosciences stock rating on pipeline progress - Investing.com
SLDB Q1 2026 Earnings: Wider-than-Expected Loss Highlights Clinical-Stage CostsProfit Cycle Analysis - careplusvn.com
Solid Biosciences (NASDAQ:SLDB) Posts Earnings Results, Beats Estimates By $0.08 EPS - MarketBeat
Solid Biosciences Inc expected to post a loss of 48 cents a shareEarnings Preview - TradingView
Solid Biosciences Inc. Stock 12‑Month Price Target Cut to $17.64, Implies 102% Upside - TradingView
Solid Biosciences Inc (SLDB) Earnings Forecast: Future EPS & Revenue Growth Estimates - tradingkey.com
Solid Biosciences files prospectus for up to $200 million at-the-market stock offering - Bitget
Wedbush Adjusts PT on Solid Biosciences to $15 From $16, Maintains Outperform Rating - Yahoo Finance
Solid Biosciences (SLDB) Eyes Key Clinical Milestones Amid High Valuation on Price-to-Sales Basis - GuruFocus
Solid Biosciences files prospectus supplement for up to $200 million stock offering - Investing.com Canada
Solid Biosciences (NASDAQ: SLDB) sets $200M stock sale capacity - Stock Titan
Solid Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Updates - The Manila Times
Solid Biosciences Q2 net loss widens on higher R&D costs - TradingView
Solid Biosciences Inc. Q2 2026: Revenue $0 Net loss $(54.8M), EPS $(0.38) — 10-Q Summary - TradingView
0.05%
0.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):